Latest Insider Transactions at Fate Therapeutics Inc (FATE)
This section provides a real-time view of insider transactions for Fate Therapeutics Inc (FATE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of FATE THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of FATE THERAPEUTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 11
2022
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
5,419
-1.69%
|
$260,112
$48.81 P/Share
|
|
Jan 11
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
14,566
-1.64%
|
$699,168
$48.79 P/Share
|
|
Jan 10
2022
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
5,596
-1.79%
|
$257,416
$46.75 P/Share
|
|
Jan 10
2022
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
7,738
-2.3%
|
$355,948
$46.76 P/Share
|
|
Jan 10
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
34,156
-2.41%
|
$1,605,332
$47.08 P/Share
|
|
Jan 03
2022
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
50,000
-6.12%
|
$2,950,000
$59.19 P/Share
|
|
Jan 03
2022
|
Cindy Tahl |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+18.59%
|
$300,000
$6.55 P/Share
|
|
Dec 20
2021
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,977
-12.64%
|
$958,620
$60.0 P/Share
|
|
Dec 20
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,437
+10.25%
|
$505,295
$35.52 P/Share
|
|
Dec 13
2021
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.91%
|
$1,175,000
$47.61 P/Share
|
|
Dec 13
2021
|
Bahram Valamehr President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+12.09%
|
$50,000
$2.73 P/Share
|
|
Dec 10
2021
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,500
-0.82%
|
$390,000
$52.42 P/Share
|
|
Dec 10
2021
|
Yu Waye Chu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+5.33%
|
$120,000
$16.32 P/Share
|
|
Nov 19
2021
|
Yu Waye Chu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,958
+32.65%
|
-
|
|
Nov 19
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,540
+34.72%
|
-
|
|
Nov 19
2021
|
Mark Plavsic Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,540
+37.9%
|
-
|
|
Nov 19
2021
|
Cindy Tahl |
BUY
Grant, award, or other acquisition
|
Direct |
60,958
+26.51%
|
-
|
|
Nov 19
2021
|
Bahram Valamehr President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
60,958
+28.01%
|
-
|
|
Nov 19
2021
|
J Scott Wolchko President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
86,475
+15.26%
|
-
|
|
Nov 18
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-4.83%
|
$1,080,000
$54.27 P/Share
|
|
Nov 18
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$40,000
$2.7 P/Share
|
|
Oct 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$1,740,000
$58.88 P/Share
|
|
Oct 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.35%
|
$90,000
$3.42 P/Share
|
|
Oct 21
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-3.6%
|
$1,800,000
$60.23 P/Share
|
|
Oct 21
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Oct 01
2021
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
50,000
-11.87%
|
$2,900,000
$58.89 P/Share
|
|
Oct 01
2021
|
Cindy Tahl |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+24.03%
|
$300,000
$6.55 P/Share
|
|
Sep 28
2021
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,460
-27.08%
|
$1,206,520
$62.53 P/Share
|
|
Sep 28
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,325
+19.43%
|
$606,375
$35.52 P/Share
|
|
Sep 13
2021
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-7.31%
|
$1,650,000
$66.75 P/Share
|
|
Sep 13
2021
|
Bahram Valamehr President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+17.15%
|
$50,000
$2.73 P/Share
|
|
Aug 19
2021
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,474
-2.03%
|
$305,712
$88.85 P/Share
|
|
Aug 19
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-4.83%
|
$1,760,000
$88.01 P/Share
|
|
Aug 19
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$80,000
$4.84 P/Share
|
|
Aug 03
2021
|
Yuan Xu |
BUY
Grant, award, or other acquisition
|
Direct |
4,744
+50.0%
|
-
|
|
Jul 23
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$2,550,000
$85.28 P/Share
|
|
Jul 23
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+3.46%
|
$90,000
$3.79 P/Share
|
|
Jul 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.4%
|
$2,580,000
$86.16 P/Share
|
|
Jul 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Jul 01
2021
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
55,534
-3.19%
|
$4,942,526
$89.97 P/Share
|
|
Jul 01
2021
|
Cindy Tahl |
BUY
Exercise of conversion of derivative security
|
Direct |
55,534
+8.61%
|
$333,204
$6.04 P/Share
|
|
Jun 14
2021
|
Mark Plavsic Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+50.0%
|
-
|
|
Jun 14
2021
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-7.29%
|
$2,225,000
$89.85 P/Share
|
|
Jun 14
2021
|
Bahram Valamehr President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+9.72%
|
$50,000
$2.82 P/Share
|
|
Jun 02
2021
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
John Mendlein |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+1.65%
|
-
|
|
Jun 02
2021
|
Shefali Agarwal |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Karin Jooss |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Robert S Epstein |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
William H Rastetter |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|